What one share of Enliven Therapeutics holds
We are a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics to help people not only live longer, but live better. We aim to address existing and emerging unmet needs with a precision medicine approach that improves survival and enhances overall well-being.
Enliven Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$1.67 |
|---|---|
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$1.06 |
| Cash and investments | $12.22 |
| Book value | $12.22 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2022 | — | −$12.05 | $0.20 | −$10.46 | — | −$21.52 |
| 2023 | — | −$2.01 | $0.00 | −$1.73 | — | $5.96 |
| 2024 | — | −$1.89 | $0.00 | −$1.56 | — | $6.33 |
| 2025 | — | −$1.83 | $0.00 | −$1.24 | — | $7.73 |
Common questions about Enliven Therapeutics
How much does one share of Enliven Therapeutics earn?
Over the last 12 months, Enliven Therapeutics lost $1.67 for each share.
Does Enliven Therapeutics pay a dividend?
Enliven Therapeutics didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Enliven Therapeutics’s book value per share?
Enliven Therapeutics’s book value is $12.22 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Enliven Therapeutics have?
Each share of Enliven Therapeutics has $12.22 of cash and investments, as of June 30, 2026.
What is Enliven Therapeutics’s free cash flow per share?
−$1.06 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
Has Enliven Therapeutics bought back shares?
Enliven Therapeutics’s share count rose about 1714% from 2022 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.